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Background: Radiation resistance presents a challenge to the effective treatment of cancer. If therapeutic compounds
were capable of resensitizing resistant tumours then a concurrent chemo-radiation treatment could be used to overcome
radiation resistance.
Methods: We have developed a phenotypic assay to investigate the response of radiation resistant breast cancer cells
grown in 3D-microtissue spheroids to combinations of radiation and established chemotherapeutic drugs. The effects
were quantified by real time high content imaging of GFP detection area over 14 days. Ten established chemotherapeutic
drugs were tested for their ability to enhance the effects of radiation.
Results: Of ten analysed chemotherapeutics, vinblastine was the most effective compound, with docetaxel and
doxorubicine being less effective in combination with radiation. To investigate the response in a model closer to
the in vivo situation we investigated the response of heterotypic 3D microtissues containing both fibroblasts and
breast cancer cells. Drug treatment of these heterotypic 3D cultures confirmed treatment with radiation plus vinblastine
to be additive in causing breast cancer growth inhibition. We have validated the screen by comparing radiation
sensitizing effects of known chemotherapeutic agents. In both monotypic and heterotypic models the concurrent
treatment of vinblastine and radiation proved more effective inhibitors of mammary cancer cell growth. The effective
concentration range of both vinblastine and radiation are within the range used in treatment, suggesting the 3D model
will offer a highly relevant screen for novel compounds.
Conclusions: For the first time comfortable 3D cell-based phenotypic assay is available, that allows high throughput
screening of compounds with radiation therapy modulating capacity, opening the field to drug discovery.
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The rapid evolution of resistance to both conventional
and small molecule therapies is a challenging problem in
oncology. One approach to overcome resistance is to use
combinatorial treatments that exploit their synergies. The
combination of chemotherapy and radiation treatment is
emerging as a potentially effective combinatorial regimen,
although the optimal mix has not been identified [1, 2].* Correspondence: natasa.anastasov@helmholtz-muenchen.de
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(http://creativecommons.org/publicdomain/zeroA major drawback in identifying potentially radiation-
sensitizing chemotherapeutic agents is the lack of high
throughput screening (HTS) vehicles to identify possibly
beneficial combinations. These are needed to replace
conventional clonogenic survival assays of radiation
treatment as these are too expensive and time consum-
ing to operate in a first-pass screening mode. Moreover,
there are growing concerns that monolayer and mono-
typic (2D) cellular screening assays may not effectively
reproduce the response of a three-dimensional (3D)
solid tumor to pharmacological compounds [3–5].
Multicellular 3D spheroid models have been proven to be
representative of in vivo tumors [6–8]. However, classicalss article distributed under the terms of the Creative Commons Attribution
s/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
Anastasov et al. BMC Cancer  (2015) 15:466 Page 2 of 103D technologies such as tumor spheroid analysis using
hanging drops, microencapsulation, and liquid overlays are
laborious and not sufficiently reproducible for use as high
throughput screens [9–12]. We have modified an existing
hanging drop 3D-microtissue technology (Insphero, AG) to
develop a high content screen to interrogate potential
radiation sensitizing compounds. Major advantage of
such new screen technology is single spheroid growth
analysis (per well) after chemo- or radiation treatment.
In validating the assay we examined a panel of ten
standard chemotherapeutic compounds for their ability to
potentiate the anti-tumour action of radiation against the
radiation resistant T47D mammary cancer cell line.
Co-culturing cancer cells with fibroblasts in 3D hetero-
typic microtissues can mimic breast cancer heterogeneity,
allowing a more physiological response to screening
[13–15]. To fully recapitulate the complexity of breast
cancer we established heterotypic cultures of normal hu-
man dermal fibroblasts (NHDF) and a panel of three
mammary cancer cell lines (T47D, MDA-MB-361 and
MDA-MB-231). Here we report the identification of vin-
blastine as a potential radiosensitizing treatment in both
monotypic and heterotypic 3D-microtissues.
Methods
Growth and maintenance of cell lines
The T47D breast cancer cell line (HTB-133), the MDA-
MB-361 (HTB-27) and the MDA-MB-231 (HTB-26) cell
lines were a kind gift from Professor M. Aubele, Institute
of Pathology, Helmholtz Center Munich. The T47D
breast cancer cell line and the GFP/RFP lentivirus modi-
fied T47D-GFP and T47D-RFP cell lines were main-
tained in RPMI 1640 (Roswell Park Memorial Institute)
medium supplemented with 10 % FCS and human insulin
(10 μg/ml). MDA-MB-231 cell line and the GFP/RFP ex-
pressing MDA-MB-231-GFP and MDA-MB-231-RFP cell
lines were maintained in DMEM (Dulbecco’s Modified
Eagle Medium) supplemented with 10 % FSC and non-
essential amino acids (Sigma Aldrich, USA). MDA-MB-361
cell line and the GFP/RFP expressing (MDA-MB-361-GFP
and MDA-MB-361-RFP) cell lines were maintained in
DMEM supplemented with 20 % FCS. Primary normal
human dermal fibroblasts (NHDF) expressing GFP
were temperature sensitive immortalized by protocols
from Sirion Biotech GmbH (GE) and were maintained
in Fibroblast growth medium (Promocell, GE) supple-
mented with 0.4 mg/ml G418. Additionally all GFP/
RFP expressing cell lines were supplemented with
0.3 μg/ml Puromycin (Sigma Aldrich, USA) for stable
cell selection of fluorescent marker expression. The human
embryonic kidney HEK293T (DSMZ, Germany) cells were
used for lentivirus productions and grown in DMEM
medium with 10 % FCS. Cultivation was performed under
standard conditions in water humified 37 °C incubator with5 % CO2, either for 2D or 3D cell analysis. Cell lines were
checked for mycoplasma contamination using the MycoA-
lert Detection Kit (Lonza Group Ltd, CH) and their identity
verified by genetic profiling using the PowerPlex® 16 System
(Eurofins/MWG Operon, GE). Research involving human
patient material and data with ethics committee approval
was not used for this study.
Lentivirus production and infection of breast cancer cell
lines
Replication-defective lentiviral particles were produced by
transient co-transfection of HEK293T cells in a 10 cm petri
dish using Lipofectamine 2000 (Life Technologies, USA)
according to the manufacturer’s instructions. Transfection
mix contained 16 μg, 8 μg and 4 μg of packaging plasmids
pMDLg/pRRE, pRSV.Rev and pMD2.G (a kind gift from D.
Trono, École polytechnique fédérale de Lausanne, CH)
and 8 μg of lentiviral transduction vector pGreenPuro
(pGP) expressing copGFP (System Biosciences, USA).
The virus particles were harvested 48 hours after transfec-
tion, cleared and concentrated as described [16]. According
to virus titer determination virus productions ranged
between 108 and 109 TU/ml and viral infection of T47D
breast cancer cells was performed using previously de-
scribed protocols [16–19]. Briefly, 2 × 105 cells per well
were infected with 4 × 105 TU/ml (2 MOI) and three
days after infection GFP expression was monitored.
Correspondingly the T47D, MDA-MB-361 and MDA-
MB-231 breast cancer cells were stable transduced with
red fluorescence protein (RFP) lentiviral expression
vectors using protocols from Sirion Biotech GmbH
(GE) and maintained with 0.3 μg/ml puromycine [20].
Stable GFP or RFP labeled cells were seeded in Gravity
PLUS™ plates (InSphero AG, CH) and treated as de-
scribed below.
Generation of monotypic tumour 3D-microtissues and
radiation treatment
Cell density in media was estimated using a hemocytometer
prior seeding the cells in (96-well) 3D hanging drop culture
plates. 3D microtissues were generated ranging from 200 to
2000 cells per well and breast cancer 3D microtissues
started with 500 cells per well were chosen as starting point
showing adequate growth kinetics and low interwell varia-
tions (bellow 10 %) for the following studies. Standard
methods describe production of spheroids using 106 cells
that are plated in 100-mm pre-coted Petri dishes to develop
mammary spheroids (within 6 to 9 days) raging in size
between 250 μm and 350 μm [7]. In our study 3D-
microtissues were formed by seeding T47D, MDA-MB-
361 and MDA-MB-231 cells into the Gravity PLUS™ 96
well plate (500 cells/well) and maturing them for 3 days
in hanging drops, followed by transfer of the single
spheroids into the Gravity TRAP™ (receiver) assay
Anastasov et al. BMC Cancer  (2015) 15:466 Page 3 of 10plates (InSphero AG, CH). After one day of recovery
(defined as day 0 of treatment), tissues were sham irra-
diated (0 Gy) or irradiated with a single acute dose of
2 Gy, 4 Gy, 6 Gy or 8 Gy with a Cs-137 irradiator
(HWM D-2000, Siemens, GE) delivered a dose rate of
0.5 Gy/min. The exposed and sham irradiated 3D-
microtissues were subsequently incubated at 37 °C with
5 % CO2 for indicated time points. The experiment was
repeated for each dose in quadruplicates (n = 4). The
3D-microtissues (spheroids) were treated with different



































Fig. 1 Growth analysis of 3D-microtissues with constitutive lentiviral-GFP e
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plot in μm2) – area quantification of spheroid growth delay after irradiation at in
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with constant excitation times (1 ms), nevertheless fluorophore saturation
fluorescence intensity cannot be used for quantificationsubsequently growth was analysed every 3 days after
treatment mostly dependent on experimental set-up
and working days (Fig. 1 and Additional file 1: Figure S1).
3D-microtissues from 8 wells were used for cell number
counts by hemocytometer. The GFP image-based area
(μm2) measurement (Additional file 1: Figure S1a) corre-
lates with increased cell number counts per spheroid, con-
firming efficient 3D-microtissue growth quantification
using green microtissue area determination (Additional
file 1: Figure S1b). Growth of 3D-microtissues was
followed in assay plates for 20 days with Operettadiation
[+ days]
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was detected after radiation treatment, confirming that absolute
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pipetting steps during assay analysis, except medium
change after 6 days and 12 days of analysis (Additional
file 1: Figure S1c). Direct quantification of 3D-microtissue
fluorescent area (Additional file 1: Figure S1) using a high
imaging platform accelerates assay quantification of
3D-microtissue growth after radiation and captures the
full range of microtissue phenotypes during analysis.
3D-microtissue growth kinetics and treatment with test
compounds
3D-microtissue growth was measured for up to 20 days
after initiation of treatment (day 0). Complete medium
change was performed on day 6 and 12. The 3D-
microtissues were treated with different concentrations of
chemotherapeutic agents at day 0 concurrent to radiation.
DMSO (1 %) was used as control solvent for generating
10 mM stock of Docetaxel, Vinblastine, Actinomycin D,
Etoposide, Staurosporine and 5-Fluorouracil. H2O was the
control solvent for Doxorubicin, Hydrocortisone, Cyclo-
hexamide and 6-Thioguanine (Sigma-Aldrich Co, USA)
treatment. Irradiation (2 Gy) was applied once at day
0 and concurrently substances (1 μl/well) were added
to 3D-microtissue Gravity-TRAP plates at indicated
concentrations.
Image analysis and 3D-microtissue growth efficiency
quantification
Imaging was performed at different time points post-
irradiation (over 20 days) using the Operetta® High Content
Imaging System (Perkin Elemer, USA). Images from a sin-
gle plate were acquired in the GFP, RFP and Brightfield
channels using the 10xNA objective in wide field mode.
Automated quantitative analysis of 3D-microtissue
sizes at the different time points was then performed
using Harmony®3.1 High Content Imaging and Analysis
Software. In the Harmony software, the Find Image Region
Building Block was then applied to the GFP or RFP chan-
nel to detect the microtissues in the well. As a next step,
the Calculate Morphology Building Block was added to
calculate the tissue area (μm2) as the final readout. Data
generated from 96 wells at different time points were nor-
malized to the starting point (day 0 of irradiation and
compound treatment) using control sham irradiated
spheroids with 1 % DMSO treatment. Inter-well variations
were less than 5 % for monotypic cultures and between 5
and 20 % for heterotypic co-cultures. For statistical ana-
lysis the Student’s t-test was used.
Generation of heterotypic 3D-microtissues and combined
treatment with compounds and radiation
For the heterotypic 3D-microtissue assays normal hu-
man dermal fibroblasts (NHDF) were GFP labelled with
lentiviral approach (Sirion Biotech, GE) and co-culturedwith RFP breast cancer cell lines (T47D, MDA-MB-361
and MDA-MB-231). NHDF-GFP (1500 cells/well) were
mixed with RFP-breast cancer cells (250 cells/well), ma-
tured for 3 days in hanging drops, followed by transfer of
the heterotypic spheroids into Gravity TRAP™ assay plates
(InSphero AG, CH). After 1 day of recovery, microtissues
were sham (0 Gy) or with 2 Gy irradiated and concurrently
compounds (vinblastine and doxorubicine) were added at
10 nM and 100 nM in quadruplicates to the assay plates.
Heterotypic 3D-microtissue growth was measured up to
20 days after initiation of treatment (day 0) and quantified
using Operetta High Content Imaging System. A dual laser
scan was performed using GFP filter (ex. 460–490 nm
and em. 500–550 nm) to measure NHDF-GFP spheroid
formation and Alexa-546 Filter (ex. 520–550 nm and em.
560–630 nm) to measure T47D-RFP, MDA-MB-361-RFP
and MDA-MB-231-RFP spheroid area formation.
Results
3D-microtissues for high content screening of radiation
sensitivity
The growth response of T47D breast cancer cells stably
transduced with a lentiviral vector expressing GFP fluores-
cent protein was followed over 20 days by high content
analysis of the (green) microtissue area (Fig. 1). Additional
file 1 shows that the area of T47D-GFP spheroids cor-
related with the change in cell numbers. Treatment
with a range of radiation doses (2–8 Gy) induced
growth delays that were detectable even at the lowest
2 Gy radiation dose tested (Fig. 1b). Fig. 1c shows rep-
resentative images of T47D-GFP 3D-microtissues used
for GFP area quantification.
To confirm the radiation effect in other mammary cancer
cells 3D-microtissues of MDA-MB-361 and MDA-MB-231
transduced with an RFP expressing lentivirus were evalu-
ated using the hanging drop plates. Figure 2a shows that
T47D-RFP and MDA-MB-361-RFP cells readily formed
well-packed multi-cellular spheroidal 3D-microtissues,
whilst MDA-MB-231-RFP cells lack the capacity to self-
aggregate and form microtissues. These latter cells could
not be analyzed in 3D monotypic microtissues. A compari-
son of the growth of T47D-RFP and MDA-MB-361-RFP
cells after irradiation confirmed that the assay was able to
detect the greater radiation sensitivity of the MDA-MB-361
cells (Fig. 2b).
Kinetics of the inhibition of 3D-microtissue growth by
cytostatic compounds
The cytostatic potential of 10 chemotherapeutic com-
pounds was determined using T47D-GFP 3D-microtissues.
Results of the three cytostatica most often used in
breast cancer treatment (docetaxel, vinblastine and
doxorubicine) are presented on Fig. 3. Efficient inhi-
bition of 3D-microtissue growth was detectable with
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Fig. 2 Growth analysis of monotypic 3D-microtissues with constitutive lentiviral-RFP expression. a Example of RFP detection for breast cancer
3D-microtissue spheroids generated from T47D-RFP, MDA-MB-361-RFP and MDA-MB-231-RFP cells (9 days after treatment), b RFP plot quantification
of MDA-MB-361 and T47D spheroid growth delay after 2 Gy irradiation at indicated time points. Data are averages ± SD (n= 4). MDA-MB-231 were not
quantified using RFP area (μm2) settings, as they were not forming consistent spheroid structures during 13 days of analyses
Anastasov et al. BMC Cancer  (2015) 15:466 Page 5 of 10300 nM of vinblastine (Fig. 3a) and 300 nM of
Docetaxel (Fig. 3b). These values correlate well with
maximum plasma level concentrations used in anti-
cancer treatment and confirm that the 3D-microtissue
assay can provide relevant information on therapeutic
potential. The results for the remaining seven compounds
are presented in Additional file 2, showing high inhibitory
effects for Actinomycin D, Etoposide, Cyclohexamide
and 5-FU.
Combined effects of radiation and chemotherapeutic
treatment
Vinblastine (Fig. 4), docetaxel and doxorubicine (Additional
file 3) were tested in combination with an acute 2 Gy
radiation exposure. Combined treatments of docetaxel
or doxorubicine with radiation did not produce any in-
crease in efficacy beyond that of the chemotherapeuticcompounds alone (Additional file 3 a-d). In contrast, vin-
blastine treatment combined with irradiation produce an
additional inhibitory effect when used in low (300 nM) con-
centration (Fig. 4b). These results were confirmed using the
CellTiter-Glo proliferation assay (Fig. 4c).
Development of heterotypic 3D-microtissues for combined
radiation and chemotherapeutics screening
As mammary tumors usually include non-cancer stromal
cells we investigated the contribution of fibroblasts, and
potential anti-tumour bystander effects by generating
heterotypic 3D-microtissues for phenotypic analysis. The
inclusion of NHDF-GFP fibroblasts did not effect spheroid
formation of T47D-RFP and MDA-MB-361-RFP, but
allowed the previously diffusely growing MDA-MB-231-
RFP cells to form 3D-microtissues (Additional file 4).
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Fig. 3 3D-microtissue growth analysis after Vinblastine, Docetaxel and Doxorubicine treatment. GFP plot (area in μm2) quantification of spheroid
growth delay after a Vinblastine, b Docetaxel and c Doxorubicine treatment at indicated time points and compound concentrations (data are
averages ± SD, n = 4)
Anastasov et al. BMC Cancer  (2015) 15:466 Page 6 of 10component in heterotypic 3D-microtissue formation using
different breast cancer cell lines. Growth of T47D-RFP in
hetertotypic 3D-microtisues was comparable to that in
monoypic cultures, whereas growth of NHDF-GFP fibro-
blasts was not detected (Fig. 5a and b).
As vinblastine demonstrated a radiosensitation effect
in monotypic cultures we examined the effect in the
3D-heterotypic cultures. The combined treatment withvinblastine and 2 Gy radiation was an effective radiosensi-
tizer in all three breast cancer heterotypic 3D-microtissues
analyzed (Fig. 5c). NHDF-GFP fibroblasts growth after
treatment was negligible (Additional file 5). Doxorubicine
did not show a significant additional effect with concur-
rent irradiation when compared to individual substance
treatment (Additional file 5), in agreement with the re-
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Fig. 4 Quantification of radiosensitizing effect after Vinblastine treatment using T47D monotypic 3D-microtissues. GFP plot (area in μm2) for control
T47D 3D-microtissue and after treatment with 0 Gy and 2 Gy irradiation using (a) 10 μM Vinblastine and (b) 300 nM Vinblastine at indicated time points.
Data are averages ± SD; * indicate statistically (t-test) significant changes to corresponding control with Vinblastine treatment at 0 Gy, *p < 0.05;
**p < 0.001. (c) T47D 3D-microtissues were treated with 0 Gy and 2 Gy radiation including 300 nM Docetaxel or 300 nM Vinblastine. 12 days
after treatment 3D-microtissues were lysed directly in assay plates and measured for luciferase activity (Cell-TiterGlo Assay). Data are averages ± SD,
* indicate statistically (t-test) significant changes to corresponding controls at 0 Gy, **p < 0.001
Anastasov et al. BMC Cancer  (2015) 15:466 Page 7 of 10Docetaxel was not analyzed using heterotypic cultures, as
radiosensitation effect was not detectable using monotypic
3D-microtissues previously.Discussion
Despite a number of preclinical studies indicating potential
radiation sensitizing effects of candidate therapeutics, few
have been tested in clinical studies. Glass and colleagues es-
timated that less than 10 % of phase I cancer clinical trials
between 2001 and 2009 combined chemical and radiation
therapy [21]. This is unusual, given that therapy with
multiple drugs is common practice and that combination
of chemo- and radiation therapy are predicted to be addi-
tive or synergistic [22]. One reason for the poor uptake of
combined therapy in clinical trials may be the often contra-
dictory results of preclinical and clinical models [23–27].
Very few studies have attempted to incorporate biological
endpoint analysis and therefore improved mechanistic
understanding between results from clinical studies and
experimental approaches is needed. Traditional clonogenic
survival and high throughput colorimetric assays are
inadequate as drug screens to identify novel radiation
sensitizers. A high content clonogenic survival drug
screen has been developed recently [28], but including
three-dimensional assays for drug screens could tre-
mendously accelerate preclinical testing in the future.The hanging drop system, the oldest cell culture tech-
nique of all, has undergone a recent rebirth [12, 29]
showing great potential for making cancer screening
assays more predictive and informative [5]. Therefore,
3D-microtissue technology has been adapted to create
a high-throughput screen capable of following changes
in cell growth in real time for up to 20 days after treat-
ment. Three different mammary tumor cell lines were
analysed in the capacity to form 3D-microtissues, con-
firming previously published data that not all mammary
cell lines are able to self-aggregate and form spheroids
[30]. Consistently cells effective in spheroid formation
(T47D and MDA-MB-361) were analysed in growth
delay after radiation confirming results from colony
formation assays published before [17]. Furthermore,
we examined ten established chemotherapeutic drugs to
determine if any are capable of sensitizing a radiation-
resistant mammary cancer cell line to a single 2 Gy dose
of radiation. We demonstrate that the combined treat-
ment of radiation and chemotherapeutics can be followed
in real time and robustly quantified by using high content
imaging platform settings and standard fluorescent area
field determination per well containing single spheroids
varying 10 % in size at start point of analysis (day 0).
From analysed cytostatica, taxanes such as paclitaxel
and docetaxel, and vinca alkaloids such as vincristine
and vinblastine, have been widely used for the treatment
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Fig. 5 Heterotypic 3D-microtissue analysis after irradiation and concurrent Vinblastine treatment. a Merged and single GFP/RFP image examples
of T47D-RFP/NHDF-GFP co-cultures with selected population for μm2 quantification after irradiation. b RFP and GFP plot (area in μm2) for
T47D-RFP and NHDF-GFP heterotypic 3D-microtissues after treatment with 0 Gy and 2 Gy irradiation. c Co-cultures of T47D-RFP; MDA-MB-361-RFP and
MDA-MB-231-RFP with NHDF-GFP growth quantification at day 11. RFP area (μm2) was analysed after 0 Gy and 2 Gy irradiation with concurrent 100
nM Vinblastine treatment. Data are averages ± SD, * indicate statistically (t-test) significant changes to corresponding control with Vinblastine treatment
at 0 Gy, *p < 0.05; **p < 0.001
Anastasov et al. BMC Cancer  (2015) 15:466 Page 8 of 10of a variety of tumors including breast cancer [31–33],
whereas docetaxel is established as one of the most ac-
tive agents against metastatic breast cancer [34].
In our analysis vinblastine emerged as the most potent
radiation sensitizing agent using monotypic 3D-microtis-
sues, suggesting that this agent can be effective when
used in combined radiation and chemotherapy treatment
[35]. In heterotypic cultures the combined treatment ofvinblastine plus radiation was even more effective using
vinblastine and indicating a cooperative bystander effect of
tumour stroma in the sensitization. The serum concentra-
tion of vinblastine during cancer therapy is estimated to
reach 10–400 nM a few hours after application [36, 37].
Furthermore, it is reported that vinblastine accumulates in
some tissues as spleen, thyroid, large and small intestine
to even higher levels, suggesting that the maximum
Anastasov et al. BMC Cancer  (2015) 15:466 Page 9 of 10concentration of vinblastine is in the range of 0.06–
28 μM in some organs. Therefore it is conceivable that
the concentration range (0.1–10 μM) we analyzed in
this study is physiologically achievable. A potentiating
effect of radiation with concurrent vinblastine treat-
ment was confirmed with monotypic and heterotypic
3D-microtissue assays (Fig. 4 and Fig. 5).
The lack of an additive effect between docetaxel and
radiation is in good agreement with reported lack of co-
operation between paclitaxel and radiation [26, 27, 38, 39].
Despite doxorubicine having excellent anti-tumor activity
no additive effect with radiation was detected in our sys-
tem. This agrees with the relatively low therapeutic index
of doxorubicine in metastatic breast cancer patients [40].Conclusions
3D-microtissue screening platforms for phenotypic drug
characterisation, such as the one presented here, can accel-
erate the timeline for drug discovery initiatives. We have
validated the screen by comparing radiation sensitizing ef-
fects of known chemotherapeutic agents. In both mono-
typic and heterotypic models the concurrent treatment of
vinblastine and radiation proved more effective inhibitors
of mammary cancer cell growth. The effective concentra-
tion range of both vinblastine and radiation are within the
range used in treatment, suggesting the 3D model will offer
a highly relevant screen for novel compounds.Additional files
Additional file 1: Cell number correlation with spheroid growth
formation. (A) GFP area (μm2) settings for high content imaging platform
analysis using monotypic 3D-microtissues, (B) GFP plot (area in μm2)
quantification of spheroid growth compared to the cell number count
per 3D-microtissue at indicated time points. (C) 3D-microtissue growth
analysis after radiation (GFP plot in μm2) – area quantification of spheroid
growth delay after irradiation at indicated time points up to 20 days with
constant time scale and different radiation doses. Data are averages ± SD
(n = 3). Major changes in growth delay were detected between day 3
and day 13 or 15 after starting point of treatment, therefore in all
subsequent Figures this time points were used for presentation.
Additional file 2: 3D-microtissue growth analysis after treatment
with chemotherapeutics. GFP plot (area in μm2) of spheroid growth
delay after (A) 5-FU, Cycloheximide, Etoposide, Actinomycin D, (B)
Staurosporine, 6-TG, and Hydrocortisone (10 μM) treatment and
quantification at indicated time points (data are averages ± SD, n = 3).
Additional file 3: 3D-microtissue growth delay quantification after
Docetaxel, Doxorubicine and 5-FU treatment with irradiation. GFP
plot (area in μm2) for control T47D 3D-microtissue and after treatment
with 0 Gy and 2 Gy irradiation using (A) 10 μM Docetaxel, (B) 300 nM
Docetaxel, (C) 10 μM Doxorubicine, (D) 300 nM Doxorubicine, (E) 10 μM
5-FU and (F) 300 nM 5-FU at indicated time points. Data are
averages ± SD, n = 4.
Additional file 4: Phenotypic growth analysis of heterotypic 3D-
microtissues. Using NHDF/GFP and RFP marked breast cancer cells (A)
T47D, (B) MDA-MB-361 and (C) MDA-MB-231 at day 1, day 6 and day 11
after 0 Gy (sham) or 2 Gy irradiation. Day 1 confirms 3D-microtissue as-
sembling of heterotypic spheroids using three different tumour cell lines
and growth efficiency following transfer to receiver plates up to 11 days.Additional file 5: Heterotypic 3D-microtissue analysis (11 days)
after irradiation and concurrent Vinblastine treatment. Co-cultures
(11 days) after 0 Gy and 2 Gy irradiation and concurrent 100 nM Vinblastine
or 100 nM Doxorubicine treatment using (A) T47D-RFP/NHDF-GFP, (B)
MDA-MB-361-RFP/NHDF-GFP and (C) MDA-MB-231-RFP/NHDF-GFP
heterotypic microtissues.
Abbreviations
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dimensional; 3D: Three dimensional; GFP: Green fluorescence protein;
RFP: Red fluorescence protein; pGP: Plasmid GreenPuro; NHDF: Normal
human dermal fibroblasts; DMSO: Dimethylsulfoxid; DMEM: Dulbecco’s
modified eagle medium; RPMI: Roswell park memorial institute.
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